Product
Supplier
Encyclopedia
Inquiry
Home > Surfactant > Cationic Surfactants > Sodium bis(2-ethylhexyl) sulfosuccinate for Sale > Dioctyl Sulfosuccinate Sodium Salt - A Pharmaceutical Grade Anionic Surfactant for Wetting.
Dioctyl Sulfosuccinate Sodium Salt - A Pharmaceutical Grade Anionic Surfactant for Wetting. buy - large image1
Dioctyl Sulfosuccinate Sodium Salt - A Pharmaceutical Grade Anionic Surfactant for Wetting. buy - image1
Dioctyl Sulfosuccinate Sodium Salt - A Pharmaceutical Grade Anionic Surfactant for Wetting. buy - image2

Dioctyl Sulfosuccinate Sodium Salt - A Pharmaceutical Grade Anionic Surfactant for Wetting.

10 Inquiries

Unit Price: Get Latest Price
CAS No.:

577-11-7

Grade:

Pharmaceutical Grade

Content:

98.5%

Port:

Hefei

Brand:

Lifang

Packaging:

5kg/drum, 10kg/drum, 15kg/drum

Price valid (until):

2025-09-26

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Felodipine,Nifedipine,Bempedoic Acid,Doxazosin mesylate,Ivabradine hydrochloride,Azilsartan KaMedoxomil

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


       Product Detail   


    Dioctyl Sulfosuccinate Sodium Salt (CAS: 577-11-7), also known as Docusate Sodium, is a high-purity pharmaceutical-grade anionic surfactant. It is widely used as a key excipient in oral solid and liquid formulations as a stool softener, and in topical products as an emulsifying and wetting agent to enhance bioavailability. Supplied by Hefei Lifeon Pharmaceutical under cGMP, it ensures consistent quality and performance for reliable formulation development.

    Shop Dioctyl Sulfosuccinate Sodium Salt - A Pharmaceutical Grade Anionic Surfactant for Wetting.-Detailed Image 1 Shop Dioctyl Sulfosuccinate Sodium Salt - A Pharmaceutical Grade Anionic Surfactant for Wetting.-Detailed Image 2

    Items Specifications
    Product Name Dioctyl sulfosuccinate sodium salt
    generic name Docusate Sodium; DSS
    IUPAC Name C₂₀H₃₇NaO₇S
    Molecular Weight 444.56 g/mol
    Water Solubility Freely soluble in water and alcohol
    Melting Point
    100.05℃


      company profile


    Founded in 2002, Hefei Lifeon Pharmaceutical Co., Ltd. was successfully listed on the main board of Shenzhen Stock Exchange in December 2020 (stock code: 003020). Now it has six pharmaceutical industrial enterprises and one chain pharmacy. It is an innovative pharmaceutical enterprise integrating drug R&D, manufacturing and commercialization, and its products involve cardiovascular, central nervous system, digestive system, topical skin medicine and ophthalmology. It won the title of "China Pharmaceutical Industry's Most Valuable Enterprise" twice, and was selected as "China Chemical Pharmaceutical Industry's Top 100 Enterprises with Comprehensive Strength" for eight consecutive years.
    It has been committed to the development and industrialization of osmotic pump technology for a long history. Lifeon’s internationally pioneering formulation technology of insoluble single-layer core osmotic pump won the first prize of Anhui Science and Technology Award. Till now, Its listed products and the industrialization ability are in the leading position in China.
    At the same time, in order to build a differentiated competitive advantage, the company has laid out moat products with higher policies and regulations limitations:
    Psychotropic drugs.
    Lifeon Pharma is one of the few designated manufacturers of psychotropic drugs and narcotic drugs in China.
    Modern Chinese Tradition Medicine
    Lifeon Pharma inherits modern Chinese medicine with clear innovative components and clear mechanism in the field of Chinese medicine.
    High-end long-acting complex injections
    Lifeon Pharma actively explores the field of high-end long-acting complex injections.
    Hefei Lifeon Pharma has formed a product pipeline with distinctive characteristics and strong market competitiveness.
    Hefei Lifeon Pharma has five industrial bases, including its own factory, Chengzhi Bio, Dayu Pharmaceutical, Jiufang Pharmaceutical and Noratec Pharmaceutical. The company has established 33 GMP production lines, including tablets, granules, capsules, ointments, gels, APIs, oral solutions, and traditional Chinese medicine extraction. Among them, the osmotic pump workshop can achieve an annual output of 1.4 billion tablets.
    In the future, Hefei Lifeon Pharma will continue to give full play to the advantages of osmotic pump technology platform, refined anti-psychotic and modern Chinese medicine, intensively cultivate and create the differentiated advantage of "specialization and novelty", provide high-quality medical products and services, and make greater contributions to healthy China.Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 3 Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 4

    Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 5 Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 6 Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 7

    Our innovation is driven by a strategic focus on attracting and nurturing top talent.

    • Introduction:  We recruit top-tier domestic and international experts in fields like drug delivery technology, monoclonal antibodies, and chemical synthesis.

    • Cultivation:  We implement structured mentorship and training programs to foster innovation and career growth within our R&D teams.

    • Collaboration:  We maintain long-term partnerships with external domain experts to integrate advanced intellectual resources directly into our projects.

    Frequently Asked Questions (FAQs)

    Q1: What is Lifeon Pharma’s core competitive advantage?

    A: Lifeon specializes in osmotic pump controlled-release technology, with internationally leading expertise in single-layer core formulations. We are one of China’s largest manufacturers of osmotic pump tablets, with an annual capacity of 1.4 billion tablets. Our product portfolio spans cardiovascular, CNS, diabetes, dermatology, and oncology, supported by 33 GMP production lines and two advanced API manufacturing sites.

    Q2: Are your manufacturing facilities compliant with international standards?

    A: Yes. Our facilities are fully cGMP-compliant, and we have passed multiple U.S. FDA audits (e.g., for DMSA in November 2024). We also hold certifications such as National High-Tech Enterprise and Anhui Province Pharmaceutical Quality Award, and we operate in accordance with ISO quality management systems.

    Q3: What product documentation can you provide?

    A: We provide comprehensive support documents including:

    Certificate of Analysis (CoA)

    GMP Compliance Certificate

    Stability Study Data

    Process Validation Reports

    Material Safety Data Sheet (MSDS)
    Customized documentation can be prepared upon request.

    Q4: Do you offer custom synthesis or contract manufacturing services?

    A: Yes. We offer custom synthesis of APIs and intermediates, and contract manufacturing for both APIs and finished dosage forms. Our strong R&D team and flexible production lines allow us to support projects from development to commercial scale.

    Q5: What is your minimum order quantity (MOQ)?

    A: MOQ is negotiable depending on the product and order frequency. We are flexible to accommodate both small-scale development batches and large commercial volumes.

    Q6: How do you ensure supply chain reliability?

    A: We have a robust dual-site production strategy with two dedicated API facilities. Our vertically integrated supply chain—from raw materials to finished products—ensures consistent supply. We also maintain long-term partnerships with reliable logistics providers to guarantee on-time delivery.

    Q7: What is your typical lead time?

    A: For commercial products in stock, lead time is generally 2–4 weeks. For custom projects or new synthesis, lead times will be confirmed based on project scope.

    Q8: Which markets do you currently serve?

    A: We supply APIs and finished products to domestic Chinese markets and have growing exports to Asia, Latin America, the Middle East, and Europe. Our products are well-positioned for both generic and branded drug markets.

    Q9: Can you supply products in accordance with USP/EP/ChP standards?

    A: Yes. Our products can be manufactured and released to meet USP, EP, ChP, or customer-specific standards. Quality and compliance are tailored to target market requirements.

    Q10: How does Lifeon support customers technically?

    A: We offer:

    Technical data packages

    Regulatory support for drug master files (DMFs)

    Formulation development assistance

    Ongoing process optimization support Our team includes PhD-level scientists and experienced engineers ready to collaborate.


    Business photos


    Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 8 Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 9 Shop Cenobamate API - High Purity Antiepileptic Drug for Partial-Onset Seizure Treatment.-Detailed Image 10

    Basic Info
    Product Name:

    Sodium bis(2-ethylhexyl) sulfosuccinate

    Other Name:

    Butanedioic acid,2-sulfo-,1,4-bis(2-ethylhexyl) ester,sodium salt (1:1);Succinic acid,sulfo-,1,4-bis(2-ethylhexyl) ester,sodium salt;Butanedioic acid,sulfo-,1,4-bis(2-ethylhexyl) ester,sodium salt;Aerosol OT-B;SV 102;Aerosol OT;Alphasol OT;Bis(2-ethylhexyl) sodium sulfosuccinate;Bis(2-ethylhexyl) S-sodium sulfosuccinate;1,4-Bis(2-ethylhexyl) sodium sulfosuccinate;Colace;Constonate;Coprol;Dioctlyn;Dioctylal;Diomedicone;Diosuccin;Diovac;Diox;Disonate;Doxol;Doxinate;Dulsivac;Duosol;Konlax;Kosate;Laxinate;Molofac;Nevax;Regutol;Revac;Sobital;Softil;Sulfosuccinic acid bis(2-ethylhexyl)ester sodium salt;Velmol;Sodium bis(ethylhexyl) sulfosuccinate;Bis(2-ethylhexyl) sulfosuccinate sodium salt;Sodium 1,4-bis(2-ethylhexyl) sulfosuccinate;Di-2-ethylhexyl sodium sulfosuccinate;Sodium dioctyl sulfosuccinate;Dioctyl sodium sulfosuccinate;DSS;Complemix;Dioctyl-Medo Forte;Diotilan;Molatoc;Molcer;Norval;Soliwax;Solusol;Sulfimel DOS;Waxsol;Di(2-ethylhexyl) sulfosuccinate sodium salt;AOT I;Dioctyl sulfosuccinate sodium;Triton GR 5;Triton GR 7;Vatsol OT;Rapisol;Aerosol GPG;Dioctyl sulfosuccinate sodium salt;Obston;Mervamine;Defilin;Aerosol OT 75;Sodium di(2-ethylhexyl) sulfosuccinate;Berol 478;Sanmorin OT 70;Alcopol O;Wetaid SR;Tex-Wet 1001;Manoxol OP;Docusate sodium;Nikkol OTP 70;Humifen WT 27G;Warcowet 060;Sodium 1,2-bis(2-ethylhexyloxycarbonyl)-1-ethanesulfonate;SBO;12640-70-9;29732-38-5;51910-13-5;52624-44-9;53023-94-2;56833-49-9;59030-04-5;60202-21-3;66812-62-2;67924-68-9;75418-10-9;76689-26-4;78207-03-1;105956-73-8;106396-28-5;110162-65-7;113255-61-1;130390-93-1;133136-80-8;135843-72-0;138893-51-3;141092-35-5;154608-80-7;201816-76-4;202352-75-8;209122-63-4;209453-97-4;336190-18-2;435344-47-1;590366-27-1;835616-33-6;1420177-77-0;1644530-78-8;1792189-42-4;1859189-40-4;1878156-39-8;2068022-40-0;2101416-24-2;2152615-06-8;2170442-07-4;2222995-19-7

    CAS No.:

    577-11-7

    Molecular Formula:

    C20H38O7S.Na

    InChIKeys:

    InChIKey=ONBWNNUYXGJKKD-UHFFFAOYSA-N

    Molecular Weight:

    444.55800

    Exact Mass:

    444.21600

    EC Number:

    209-406-4

    HScode:

    2914509090

    Categories:

    Cationic Surfactants

    Characteristics
    PSA:

    118.18000

    XLogP3:

    4.89030

    Appearance:

    Dioctyl sodium sulfosuccinate is an odorless colorless to white waxy solid. Sinks and mixes slowly with water. (USCG, 1999)

    Density:

    1.1

    Melting Point:

    176 °C

    Boiling Point:

    360 °C

    Flash Point:

    199ºC

    Water Solubility:

    H2O: 1.5 g/100 mL (25 ºC)

    Storage Conditions:

    2-8ºC

    Toxicity:

    LD50 oral in rat: 1900mg/kg

    Odor:

    CHARACTERISTIC ODOR

    Hazard Identification

    Classification of the substance or mixture

    Skin irritation, Category 2

    Serious eye damage, Category 1

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Danger

    Hazard statement(s)

    H315 Causes skin irritation

    H318 Causes serious eye damage

    Precautionary statement(s)
    Prevention

    P264 Wash ... thoroughly after handling.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    Response

    P302+P352 IF ON SKIN: Wash with plenty of water/...

    P321 Specific treatment (see ... on this label).

    P332+P317 If skin irritation occurs: Get medical help.

    P362+P364 Take off contaminated clothing and wash it before reuse.

    P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

    P317 Get medical help.

    Storage

    none

    Disposal

    none

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Capsules of the docusate salts should be stored in tight containers at 15-30 degrees C; docusate sodium solution should be stored in tight containers, and docusate sodium syrup should be stored in tight, light-resistant containers.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Felodipine,Nifedipine,Bempedoic Acid,Doxazosin mesylate,Ivabradine hydrochloride,Azilsartan KaMedoxomil

    Location:

    LIFANG FACTORY ,NO.669,CHANGJIANG ROAD WEST, HEFEI CITY

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Average lead Time:

    15

    Total Annual Revenue:

    Above $100 million

    Total Employees:

    501-1000

    Year of Establishment:

    2002

    Founded in 2002, Hefei Lifeon Pharmaceutical Co.,Ltd. is a joint-stock enterprise integrating drug R&D, manufacturing and sales. It owns 5 pharmaceutical industrial enterprises and 1 pharmaceutical retail chain enterprise. It covers the full range of production including APIs, traditional Chinese medicine extracts, Chinese patent medicines and chemical pharmaceutical preparations, etc. Moreover, Lifeon has the largest osmotic pump preparation production base in China.

    In 2013, the post-doctoral research workstation officially started operation.

    In 2018, Succimer API passed FDA inspection with zero deficiencies.

    In 2020, Lifeon listed on Shenzhen Stock Exchange.

    In 2023, a new API factory called Hefei Dayu Pharmaceutical Co.,Ltd obtained the DML and started production.

    In 2024, Doxazosin Mesylate, and Prilocaine APIs passed NMPA GMP inspection. Succimer API received renewed FDA certification. Completed registration applications for 6 API varieties within the same year.

    In the past 23 years, Lifeon has obtained numerous honors, including national high-tech enterprise, innovative enterprise in Anhui Province, enterprise technology center in Anhui Province, engineering technology research center for sustained and controlled release of drugs in Anhui Province, etc. For eight consecutive years, it has been selected as one of the “China's Top 100 Chemical and Pharmaceutical Industrial Enterprises with Comprehensive Strength”.


  • Inquiry History
    10 Inquiries
    Country Product Purchase Quantity Date Posted
    Vietnam

    Dioctyl sodium sulfosuccinate

    0.8 MT Oct 24, 2025
    Russia

    Sodium bis(2-ethylhexyl) sulfosuccinate

    16 MT May 19, 2025
    India

    Doss-40 %

    30.00 MT Jun 6, 2024
    Greece

    Sorpol 5050

    1 MT Jun 6, 2024
    Mexico

    Dioctyl sodium sulfosuccinate

    8 TON Jan 24, 2024
    India

    Sodium Dioctyl Sulfosuccinate

    1 20' Fcl Nov 25, 2024
    Indonesia

    Dioctyl Sodium Sulfosuccinate

    1 20' Fcl Oct 22, 2024
    China

    Dioctyl sulfosuccinate

    200 KG Feb 26, 2024
    Spain

    SORPOL 5050

    1 MT Jul 3, 2025
    United Arab Emirates

    Sodium bis(2-ethylhexyl) sulfosuccinate

    100 G Feb 24, 2024
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.